Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis

Journal of Psychopharmacology

Volumn 25, Issue 5, 2011, Pages 646-666

  Chung, Albert Kk ^a   Chua, Siew Eng ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Bazett's correction; meta analysis; QT interval; Second generation antipsychotics

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

ARTICLE; BAZETT CORRECTED QT INTERVAL; DRUG DOSE COMPARISON; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK; SCHIZOPHRENIA;

EID: 79955445368     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110376685     Document Type: Article

References (109)

1. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol. 2001 ; 21: 8-13 (Pubitemid 32096744)
2. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991 ; 83: 1888-1894
3. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QT interval variables from 24 hour electrocardiography and the two year risk of sudden death. Br Heart J. 1993 ; 70: 43-48 (Pubitemid 23243744)
4. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003 ; 289: 2120-2128
5. Practice Guidelines for the Treatment of Patients with Schizophrenia. 2 nd edn 2004 :
6. Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, et al. Minimizing the risks associated with significant QTc prolongation in people with schizophrenia: a consensus statement by the Cardiac Safety in Schizophrenia Group. Australas Psychiatry 10. 2002 ;: 115-124 (Pubitemid 34763890)
7. Arvanitis LA, Miller BG. Multiple fixed doses of 'Seroquel' (Quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997 ; 42: 233-246 (Pubitemid 27325811)
8. Auquier P, Lacon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. Pharmacoepidemiol Drug Safety. 2006 ; 15: 873-879 (Pubitemid 44941640)
9. Azorin J, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol. 2006 ; 21: 49-56 (Pubitemid 43175123)
10. Bagnall AM, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews.. 2000 ; ( Issue 4 ):
11. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S, the Olanzapine HGAP Study Group . Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996a ; 124: 159-167
12. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, the Olanzapine HGAD Study Group . Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996b ; 14: 111-123 (Pubitemid 26050500)
13. Bhattacharjee J, El-Sayeh HGG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews. 2008 ; ( Issue 3 ):
14. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol. 1996 ; 16: 158-169 (Pubitemid 26141753)
15. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1997 ; 171: 502-508 (Pubitemid 27527317)
16. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005 ; 50: 1S - 56S
17. Chan H, Lin W, Lin S, Hwang T, Su TT, Chiang S, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry. 2007 ; 68: 29-36 (Pubitemid 46220121)
18. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992 ; 85: 295-305
19. Review Manager (RevMan) Version 5.0.20 [Computer program]. Copenhagen: The Nordic Cochrane Centre. ; 2009 :
20. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2001 ; 158: 765-774 (Pubitemid 32429846)
21. Curran MP, Perry CM. Amisulpride. A review of its use in the management of schizophrenia. Drug. 2001 ; 61: 2123-2150 (Pubitemid 33135193)
22. Czekalla J, Kollack-Walker S, Beasley CM. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. J Clin Psychiatry. 2001a ; 62: 35-40 (Pubitemid 32154140)
23. Czekalla J, Beasely CM, Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001b ; 62: 191-198 (Pubitemid 32270094)
24. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews. 2005 ; ( Issue 2 ):
25. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 ; 315: 629-634 (Pubitemid 27387172)
26. El-Sayeh HGG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews. 2006a ; ( Issue 2 ):
27. El-Sayeh HGG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Systematic review. Br J Psychiatry. 2006b ; 189: 102-108
28. EUSPC31AUG05. Zyprexa product insert.. 2005 ;:
29. The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products. 1997 :
30. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. 2005a :
31. The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Note for Guidance on the Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. 2005b :
32. Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995 ; 17: 366-378
33. Feinstein RE. Cardiovascular effects of novel antipsychotic medications. Heart Disease. 2002 ; 4: 184-190 (Pubitemid 34670486)
34. Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced Torsade de Pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004 ; 15: 475-495 (Pubitemid 38510109)
35. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009 ; 65: 510-517
36. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. 2002 :
37. S7B Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Guidance for Industry.. 2005 ;:
38. Gilbody S, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews. 2000 ; ( Issue 3 ):
39. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc Interval, Torsade de Pointes, and sudden death. Am J Psychiatry. 2001 ; 158: 1774-1782 (Pubitemid 33054769)
40. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005 ; 80: 45-53 (Pubitemid 41587462)
41. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002 ; 3: 479-498 (Pubitemid 34520859)
42. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and Torsade de Pointes. Am Heart J. 2007 ; 153: 891-899 (Pubitemid 46809861)
43. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, Torsade de Pointes and sudden death. Drugs. 2002 ; 62: 1649-1671 (Pubitemid 34848372)
44. Hamann J, Kissling W, Leucht S, Rummel-Kluge C. New generation antipsychotics for first episode schizophrenia. Cochrane Database of Systematic Reviews. 2003 ; ( Issue 4 ):
45. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004 ; 24: 62-69 (Pubitemid 38134167)
46. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002 ; 325: 1070-1074
47. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ. 2003 ; 327: 557-560
48. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT Green S, ed. The Cochrane Collaboration. West Sussex: Wiley-Blackwell ; 2008 :
49. Hodges M. Rate correction of the QT interval. Cardiac Electrophysiol Rev. 1997 ; 3: 360-363 (Pubitemid 127503231)
50. Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews. 2003 ; ( Issue 2 ):
51. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin Trials. 1996 ; 17: 1-12 (Pubitemid 26120810)
52. Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews. 2006 ; ( Issue 2 ):
53. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007 ; 68: 832-842 (Pubitemid 47015481)
54. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet. 2008 ; 371: 1085-1097 (Pubitemid 351418005)
55. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002 ; 63: 763-771
56. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006 ; 21: 21-28 (Pubitemid 43175119)
57. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmidt F, Lewis R, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2009 ; ( Issue 2 ):
58. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002 ; 450: 37-41
59. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis on of placebo-controlled trials. Mol Psychiatry. 2009a ; 14: 429-447
60. Leucht S, Carves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009b ; 373: 31-41
61. Leucht S, Kamossa K, Rummel-Kluge C, Carves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparions of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009c ; 166: 152-163
62. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database of Systematic Reviews. 2005 ; ( Issue 3 ):
63. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectives of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 ; 353: 1209-1223 (Pubitemid 41345943)
64. Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol. 2005 ; 8: 615-629 (Pubitemid 41400893)
65. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Arch Intern Med. 2005 ; 165: 969-701
66. Sertindole Monograph.. 2006 ;:
67. McEvoy JP, Daniel DG, Carson WH, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res. 2007 ; 41: 895-905 (Pubitemid 47260697)
68. Min SK, Rhee CS, Kim C, Kang D. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 34. 1993 ; (2): 179-190
69. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet. 1998 ; 352: 609-613 (Pubitemid 28380142)
70. Moher D, Cook DJ, Eastwood S, Olkin I, Renniw D, Stroup DF, for the QUOROM group . Improving the quality of reports meta-analyses of randomized controlled trials: the QUOROM statement. Lancet. 1999a ; 354: 1896-1900
71. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999b ; 3: 19-24
72. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. A review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004 ; 164: 943-948 (Pubitemid 38581512)
73. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. 2002 :
74. NICE implementation update report: atypical antipsychotic drugs for the treatment of schizophrenia. 2008 :
75. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National clinical practice guideline number 82. 2009 :
76. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995 ; 166: 712-726
77. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997 ; 96: 265-273 (Pubitemid 27428238)
78. Peuskens J, Bech P, Moller H, Bale R, Fleurot O, Rein W. Amisulpride vs risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res. 1999 ; 88: 107-117 (Pubitemid 29507525)
79. Zeldox Monograph.. 2002 ;:
80. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003 ; 60: 681-690 (Pubitemid 36818630)
81. Price LH. Correspondance. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009 ; 360: 2137-2137
82. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003 ; 348: 1866-1874 (Pubitemid 36532312)
83. FDA Background on ZeldoxTM (Ziprasidone Hydrochloride capsules) Pfizer, Inc. Cardio Review. 2000 :
84. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001 ; 58: 1161-1167 (Pubitemid 33121508)
85. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009 ; 360: 225-235
86. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000 ; 355: 1048-1052 (Pubitemid 30162807)
87. Roden DM. Drug-Induced prolongation of the QT interval. N Engl J Med. 2004 ; 350: 1013-1022 (Pubitemid 38269278)
88. Consensus statement on high-dose antipsychotic medication. Council Report CR 138, 24. 2006 ;:
89. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009 ; 110: 80-89
90. Saha S, Chant D, Mcgrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007 ; 64: 1123-1131 (Pubitemid 47529346)
91. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fund Clin Pharmacol. 2002 ; 16: 147-156 (Pubitemid 34587799)
92. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf. 2008 ; 7: 181-194 (Pubitemid 351447701)
93. Silveira da Mota Neto JI, Soares B, Silva de Lima M. Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews. 2002 ; ( Issue 2 ):
94. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997 ; 54: 549-557 (Pubitemid 27258553)
95. Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews. 2004 ; ( Issue 2 ):
96. Sterne JAC, Becker BJ, Egger M The Funnel Plot. Publication Bias in Meta-analysis. Prevention, Assessment and Adjustments. West Sussex: John Wiley & Sons Ltd ; 2005: 75-98.
97. Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 ; 20: 243-251 (Pubitemid 41192144)
98. Straus JM, Bleumink GS, Dieleman JP, Lei JVD, Jong GW't , Kingma JH, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004 ; 164: 1293-1297 (Pubitemid 38828879)
99. Taylor D, Paton C, Kerwin R The Maudsley Prescribing Guidelines. 10 th edition London: Informa Healthcare ; 2009: 101-106.
100. Thompson SG. Systematic review: why sources of heterogeneity in meta-analysis should be investigated. BMJ. 1994 ; 309: 1351-1355 (Pubitemid 24345976)
101. Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden in clinical practice. Toxicol Appl Pharmacol. 2004 ; 199: 52-60 (Pubitemid 39099455)
102. Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W, et al. Atypical antipsychotics. From potassium channels to Torsade de Pointes and sudden death. Drug Safety. 2005 ; 28: 35-51
103. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997 ; 17: 407-418 (Pubitemid 27414397)
104. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews. 2000 ; ( Issue 2 ):
105. Van Driel ML, De Sutter A, De Maeseneer J, Christiaens T. Searching for unpublished trials in Cochrane reviews may not be worth the effort. J Clin Epidemiol. 2009 6 January 2009 ; 62: 838-844
106. Warner JP, Barnes TRE, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 1996 ; 93: 311-313 (Pubitemid 26148719)
107. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000 ; 25: 154-160
108. Witchel HJ, Hancox JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia and sudden death. J Clin Psychopharmacol. 2003 ; 23: 58-77 (Pubitemid 36164427)
109. Zarate CA, Patel J. Sudden cardiac death and antipsychotic drugs. Do we know enough?. Arch Gen Psychiatry. 2001 ; 58: 1168-1171 (Pubitemid 33121509)